HomeHeroesDe NovoDiscoveryGene ScanCDx Pathway♻️ Repurposing🚦 GatesModelsQuantum🧪 Wet LabSchedules🎛️ Control🧬 CIFOG📈 Milestones🧬 BioBrain🧠 NPEADArchitecture🔬 RODE🧠 Cortex-RWorkspace🧠 V2🧠 V3📦 Knowledge💰 Revenue🧪 Tests📊 Costs📚 Datasets

🧬 R3HCC1 — Discovery Report

📄 Autonomous discovery by Cortex · 2026-05-22

GeneR3HCC1
Full NameR3H Domain And Coiled-Coil Containing 1
Target ProteinR3HCC1_protein
Cancer TypePancreatic
GradeA+
PriorityHIGH
Stagelead_candidate
NoveltyFIRST-IN-CLASS (0 ChEMBL)
🧬 BioBrain⚖️ Decisions

Scientific Hypothesis

"R3HCC1 regulates RNA processing enabling tumor adaptive splicing. Blocking it disrupts cancer-specific transcript variants."

Mechanism of Action

Pathway: R3HCC1 → RNA processing → splicing regulation → tumor adaptation

Clinical Angle: Disrupt adaptive splicing in pancreatic cancer

Docking Results

MetricValue
Best Vina Score-8.8 kcal/mol
Best Molecule (SMILES)O=C(Nc1ccc2ncccc2c1)c1cnc2ccccc2c1
Molecular Weight299.333 Da
QED / DCSAL0.707
Molecules Tested10
Docking Methodsmina (real GPU, g4dn.xlarge)
Receptor SourceAlphaFold v4

5-Dimension Scoring

🎯 Binding: 0.88 🔬 Pathway: 0.86 💡 Innovation: 0.95 💊 Therapy: 0.88 ⭐ Novelty: 1.0 🧬 BioBrain⚖️ Decisions

Total Score: —

Governance

PQM StatusISSUED
QCM Trust1.0
Ledger Logged✅ SHA-256 hash chain
Evidence IDRO-R3HCC1
Authoritymarcus_60 (sole override)

Conclusion

R3HCC1 is a FIRST-IN-CLASS (0 ChEMBL) target with A+ grade binding affinity (-8.8 kcal/mol). The mechanistic hypothesis (R3HCC1 → RNA processing → splicing regulation → tumor adaptation) provides a clear therapeutic rationale for Pancreatic. Disrupt adaptive splicing in pancreatic cancer. Recommended for wet lab validation.

MindNetQ Inc. — Governed Intelligence for Precision Medicine
Report generated by Cortex autonomous discovery pipeline. All decisions ledger-hashed.